Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

quality of life

28th Oct 2025

Vagus nerve stimulation therapy for severe childhood epilepsy over 2 years: plain language summary

28th Oct 2025

Plain language summary of POLARIS: real-world palbociclib effectiveness and life quality impact

18th Jul 2025

Plain language summary: research findings on eptinezumab for migraine prevention in patients who didn’t respond to previous treatments

27th May 2025

Plain language summary: The IPSOS study comparing atezolizumab versus standard chemotherapy for non-small cell lung cancer patients unsuitable for platinum treatment

23rd May 2025

Plain language summary: how patients reported their experiences with avalglucosidase alfa and alglucosidase alfa in the COMET trial

17th Mar 2025

A plain language summary of the TROPiCS-02 study: impact of sacituzumab govitecan on quality of life in patients with HR-positive/HER2-negative breast cancer

23rd Sep 2024

Impact of extended tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM)

Long-chain fatty acid oxidation disorders (LC-FAOD for short) are a group of rare conditions where the body cannot use stored fat for energy. This leads to symptoms and health problems that can be life-threatening, but the impact of LC-FAOD on the everyday life of people with LC-FAOD and their caregivers has not been well studied.
30th Apr 2024

A plain language summary of a survey- the impact of long-chain fatty acid oxidation disorders (LC-FAOD)

11th Apr 2023

Plain Language Summary: long-term survival in people being treated with tafamidis for transthyretin amyloid cardiomyopathy

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy